drugset / Trial / NCT02701257

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

NCT02701257

RandomizedCrossoverOpen-labelTreatment

Summary

This study will compare two different models of a wearable bionic pancreas device (the iPhone-based bionic pancreas vs. the iLet bionic pancreas) in adult participant with type 1 diabetes. Both bionic pancreas devices measure glucose levels every five minutes and then give insulin and/or glucagon automatically to regulate the blood glucose (BG).

Timeline

Start
2016-03
Primary completion
2018-05
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lilly Glucagon Unknown
Subject Xeris Xerisol glucagon Unknown